Showing 1281-1290 of 2531 results for "".
- European Commission Approves Libtayo as First Immunotherapy for Patients with Advanced BCChttps://practicaldermatology.com/news/european-commission-approves-libtayo-as-first-immunotherapy-for-patients-with-advanced-bcc/2460851/The PD-1 inhibitor Libtayo® (cemiplimab, Regeneron/Sanofi) is approved by the European Commission to treat adults with locally advanced or metastatic basal cell carcinoma (BCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI). Libtayo is now approved for thr
- FDA Approves Expanded Use of the RECELL System for Extensive Burns and Pediatric Patientshttps://practicaldermatology.com/news/fda-approves-expanded-use-of-the-recell-system-for-extensive-burns-and-pediatric-patients/2460831/The U.S. Food and Drug Administration (FDA) approved expanded use of the RECELL System in combination with meshed autografting for the treatment of all sizes of acute full-thickness thermal burn wounds for both pediatric and adult patients. Specifically, RECELL is now in
- Allergan Aesthetics, Botox Cosmetic Unveil "See Yourself" Campaign with Real Stories from Real Patientshttps://practicaldermatology.com/news/allergan-aesthetics-botox-cosmetic-unveil-see-yourself-campaign-with-real-stories-from-real-patients/2460828/Allergan Aesthetics is launching "See Yourself," a new campaign featuring documentary-style shorts that tell the stories of real Botox Cosmetic patients. Watch 'See Yourself' shorts at www.BotoxCosmetic.com and @Bot
- CorEvitas Enrolls 15,000 Patients in its Psoriasis and AD Registrieshttps://practicaldermatology.com/news/corevitas-enrolls-15000-patients-in-its-psoriasis-and-ad-registries/2460795/CorEvitas has enrolled more than 15,000 patients with immune-mediated skin diseases in the CorEvitas registries for moderate to severe psoriasis and atopic dermatitis (AD). This milestone was achieved by building on the company's real-world evidence program and dermatolog
- Minimizing Risks of Cosmetic Procedures in Patients with Darker Skin Typeshttps://practicaldermatology.com/news/minimizing-risks-of-cosmetic-procedures-in-patients-with-darker-skin-types/2460784/With cosmetic procedures in high demand during the pandemic, Cedars-Sinai dermatologist Jasmine Obioha, MD, has seen an unfortunate side effect: botched treatments for patients of color. When performed improperly, procedures such as chemical peels and laser hair removal can inflame and
- Kintor Doses First Group of Acne Patients in Phase I/II Clinical Trial of Pyrilutamidehttps://practicaldermatology.com/news/kintor-doses-first-group-of-acne-patients-in-phase-iii-clinical-trial-of-pyrilutamide/2460752/Kintor Pharmaceutical Limited successfully dosed the first group of patients in the clinical trial of Pyrilutamide as a treatment for the acne vulgaris. The Phase I/II clinical trial in China is a randomized, double-blind, placebo-controlled clinical study to evalu
- DecisionDx-Melanoma Accurately Predicts Patient Outcomes in Cutaneous Melanomahttps://practicaldermatology.com/news/decisiondx-melanoma-accurately-predicts-patient-outcomes-in-cutaneous-melanoma/2460746/Castle Biosciences, Inc.’s DecisionDx-Melanoma is a significant, independent predictor of patient outcomes in cutaneous melanoma. DecisionDx-Melanoma is Castle’s gene expression profile test that uses an individual patient’s tumor biology to predict risk of cutane
- AAD Honors Dr. Ginette Okoye with National Patient Care Hero Award for COVID-19 Testing Workhttps://practicaldermatology.com/news/aad-honors-dr-ginette-okoye-with-national-patient-care-hero-award-for-covid-19-testing-work/2460729/The American Academy of Dermatology (AAD) named board-certified dermatologist Ginette Okoye, MD, FAAD a Patient Care Hero for establishing a dedicated COVID-19 community testing site in a historically underserved neighborhood in northeast Washington, DC. Amid the initial surge in COVID-
- Dermata Doses First Patient in Phase 1b Trial of Topical DMT310 for Mild-to-Moderate Psoriasishttps://practicaldermatology.com/news/dermata-doses-first-patient-in-phase-1b-trial-of-topical-dmt310-for-mild-to-moderate-psoriasis/2460726/Dermata Therapeutics, Inc. dosed its first patient in a Phase 1b trial of DMT310 for the treatment of mild-to-moderate psoriasis. DMT310 is currently being investigated to treat multiple inflammatory skin diseases. It consists of a once-weekly topical treatment with both mech
- NRS Launches Updated Version of "Understanding Rosacea" for Patientshttps://practicaldermatology.com/news/nrs-launches-updated-version-of-understanding-rosacea-for-patients/2460721/The National Rosacea Society has updated its most popular educational booklet. The new edition of “Understanding Rosacea” incorporates the updated standard classification and pathophysiology of rosacea, developed by a consensus committee and review panel of 28 rosacea experts worldwid